Century Therapeutics (IPSC) Reports Positive Clinical Data for Three Pipeline Candidates in Autoimmune and Diabetes Programs
Century Therapeutics (IPSC) disclosed positive Phase 1/2 data for CNTY-101 and preclinical progress for CNTY-813 and CNTY-308 in an SEC 8-K filing.